Barbara Angehrn Pavik, Asceneuron CEO
July 16, 2024 03:00 AM EDT
Financing
Startups

Alzheimer's biotech As­ceneu­ron rais­es $100M to see if it can com­pete with Lil­ly, Bio­gen on tau

Kyle LaHucik

Senior Reporter

A small Swiss biotech has raised a $100 mil­lion Se­ries C to start test­ing its oral small mol­e­cule for Alzheimer’s dis­ease in a Phase 2 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times